Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Spherix Global Insights

< Previous 1 2 3 Next >
Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights Expands into Financial Services, Empowering Asset Managers and Hedge Funds with Critical Pharmaceutical Market Insights
From Spherix Global Insights
Via GlobeNewswire
Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
From Spherix Global Insights
Via GlobeNewswire
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
From Spherix Global Insights
Via GlobeNewswire
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
From Spherix Global Insights
Via GlobeNewswire
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising Advances in Gene Therapies
From Spherix Global Insights
Via GlobeNewswire
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease
From Spherix Global Insights
Via GlobeNewswire
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Conflicting Views Between Epileptologists and General Neurologists Hinder Adoption of New Refractory Epilepsy Treatments
From Spherix Global Insights
Via GlobeNewswire
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
From Spherix Global Insights
Via GlobeNewswire
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Continued Unmet Needs and Track New Launches
From Spherix Global Insights
Via GlobeNewswire
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights Appoints Leigh Anne Siino as Chief Revenue Officer
From Spherix Global Insights
Via GlobeNewswire
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
From Spherix Global Insights
Via GlobeNewswire
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
From Spherix Global Insights
Via GlobeNewswire
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
From Spherix Global Insights
Via GlobeNewswire
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
From Spherix Global Insights
Via GlobeNewswire
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
From Spherix Global Insights
Via GlobeNewswire
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
From Spherix Global Insights
Via GlobeNewswire
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
From Spherix Global Insights
Via GlobeNewswire
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
From Spherix Global Insights
Via GlobeNewswire
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
From Spherix Global Insights
Via GlobeNewswire
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
From Spherix Global Insights
Via GlobeNewswire
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
From Spherix Global Insights
Via GlobeNewswire
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
From Spherix Global Insights
Via GlobeNewswire
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
From Spherix Global Insights
Via GlobeNewswire
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
From Spherix Global Insights
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.